Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation

J. Kapelushnik, A. Nagler, R. Or, E. Naparstek, A. Ackerstein, S. Samuel, S. Morecki, C. Nabet, S. Slavin

Research output: Contribution to journalArticlepeer-review

Abstract

We describe a 17-year-old male patient with chronic myelogenous leukemia (CML) in hematologic and cytogenetic relapse 4 months post-non-T cell-depleted allogeneic bone marrow transplantation for accelerated CML. Two sequential buffy coat transfusions with donor peripheral blood cells (8.9 and 4.8 x 107 cells/kg), the second transfusion in combination with in vivo activation of donor cells by human recombinant interleukin-2 (rIL-2) 6 x 106 IU/m2 subcutaneously for 3 days, failed to induce remission. The patient responded to an infusion of donor peripheral blood lymphocytes (3.3 x 107 cells/kg) pre-activated in vitro with rIL-2 and additionally activated in vivo with rIL-2, 6 x 106 IU/m2/day subcutaneously for 3 days. Elimination of the Philadelphia (Ph) clone was confirmed by cytogenetic analysis showing a normal male karyotype and by disappearance of the bcr/abl transcript, using the polymerase chain reaction (PCR). At present, the patient is 26 months post-treatment with no evidence of disease, but with chronic graft-versus-host disease. Our data indicate that allogeneic activated cell therapy (allo-ACT) may provide antitumor effector cells that successfully induce graft-versus-leukemia (GVL) effects even when cell therapy with donor buffy coats was insufficient.

Original languageEnglish
Pages (from-to)1153-1156
Number of pages4
JournalBone Marrow Transplantation
Volume18
Issue number6
StatePublished - Dec 1996
Externally publishedYes

Keywords

  • Activated allogeneic cell therapy
  • BMT
  • CML

Fingerprint

Dive into the research topics of 'Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation'. Together they form a unique fingerprint.

Cite this